Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ensysce Biosciences Reports Completion Of A Constructive End Of Phase 2 Meeting With FDA Regarding Its Lead 'Next Generation' Analgesic, PF614; Phase 3 Program Expected To Begin Enrollment In Mid-2024

Author: Benzinga Newsdesk | January 31, 2024 09:06am

"We are appreciative of the guidance provided by the FDA to help us properly position PF614 as we progress through clinical trials and supporting studies in order to mitigate the risk of regulatory hurdles in our go-to market plan," commented Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce.

Posted In: ENSC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist